Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1971 1
1984 1
1994 1
1996 1
1999 2
2000 2
2001 2
2002 1
2003 2
2004 5
2005 4
2006 7
2007 5
2008 3
2009 8
2010 4
2011 5
2012 2
2013 14
2014 16
2015 12
2016 9
2017 16
2018 17
2019 11
2020 22
2021 12
2022 12
2023 8
2024 14
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: pascal l. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Forgeard N, et al. Among authors: pascal l. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. Blood. 2024. PMID: 38096365 Free article. No abstract available.
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Willekens C, et al. Among authors: pascal l. Blood Cancer J. 2025 Apr 17;15(1):68. doi: 10.1038/s41408-025-01269-x. Blood Cancer J. 2025. PMID: 40246832 Free PMC article.
Dietary methionine restriction started late in life promotes healthy aging in a sex-specific manner.
Hernández-Arciga U, Stamenkovic C, Yadav S, Nicoletti C, Albalawy WN, Al Hammood F, Gonzalez TF, Naikwadi MU, Graham A, Smarz C, Little GJ, Williams SG, McMahon B, Sipula IJ, Vandevender AM, Chuan B, Cooke D, Pinto AFM, Flores LC, Hartman HL, Diedrich JK, Brooke RT, Alder JK, Frahm KA, Pascal LE, Stolt E, Troensegaard H, Øvrebø B, Elshorbagy A, Molina E, Vinknes KJ, Tan RJ, Weisz OA, Bueno M, Eickelberg O, Steinhauser ML, Finkel T, Ables GP, Ikeno Y, Olsen T, Sacco A, Jurczak MJ, Sukoff Rizzo SJ, Parkhitko AA. Hernández-Arciga U, et al. Among authors: pascal le. Sci Adv. 2025 Apr 18;11(16):eads1532. doi: 10.1126/sciadv.ads1532. Epub 2025 Apr 16. Sci Adv. 2025. PMID: 40238871 Free PMC article.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P. Mekinian A, et al. Among authors: pascal l. Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14. Leukemia. 2022. PMID: 36104395 Clinical Trial. No abstract available.
Teclistamab for relapsed refractory multiple myeloma patients on dialysis.
Lebreton P, Lachenal F, Bouillie S, Pica GM, Aftisse H, Pascal L, Montes L, Macro M, Johnson N, Harel S, Fernandez M, De Renzis B, Lioure B, Lazareth A, Javelot M, Louni C, Huart A, Perrot A. Lebreton P, et al. Among authors: pascal l. Br J Haematol. 2024 Nov;205(5):2077-2079. doi: 10.1111/bjh.19772. Epub 2024 Sep 14. Br J Haematol. 2024. PMID: 39275880 No abstract available.
206 results